EMEA-003258-PIP02-23 - paediatric investigation plan
retatrutide
PIPHuman
Key facts
Active substance
retatrutide
Therapeutic area
Metabolism and nutrition disorders
Decision number
P/0336/2024
PIP number
EMEA-003258-PIP02-23
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of obesity
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Eli Lilly And Company Limited email: EU_PAEDIATRIC@lilly.com phone: +44 1256315000
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date
Compliance check done
No
Decision
P/0336/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for retatrutide (EMEA-003258-PIP02-23)